Analysis of BRAF-mutant foci progressing via dysplastic stages to low- and high-grade carcinoma revealed a preferred sequence of events in mouse serrated tumor progression [61]: following the initiating BRAF mutation, MAPK activity was only mildly enhanced. The gene discussed is BRAF; the disease is neoplasm.